AKBA - akebia.com Operating income before deduction of amortization

Brandmark of Akebia Therapeutics Inc (AKBA)

FDA approval of Vafseo has opened access to new clinics, consolidating the position of Akebia Therapeutics (AKBA). Stable demand for anemia treatments provides the company with predictable revenue. The EBITDA volume demonstrates the efficiency of core operations, while the value of 0.00 reflects the metric's balance. The team is sustained by a strong medical mission, an ethical approach to patients, and attractive stock option programs.

akebia.com (AKBA) - Profit before payment of interest, taxes and amortization from 11/23/2025 to 11/18/2026

akebia.com - analytical breakdowns and key metrics (AKBA)

Summary company analytics:AKBA (akebia.com)
Manufactured product of Akebia Therapeutics

Stable demand for renal anemia therapies provides Akebia Therapeutics (AKBA) with a steady inflow of liquidity. This indicator captures the volume of cash generated by the core business before taxes and depreciation. The growth of this metric confirms the effectiveness of the commercial model and the company's ability to self-finance. Investors should evaluate the volatility of these values to mitigate capital shortage risks. An analysis of quarterly EBITDA confirms the long-term financial stability of the structure.